Dupuytren’s disease (DD) is a fibroproliferative disorder that affects the palmar aponeurosis and causes flexure contractures of the digits. Treatment is typically advised with flexion contracture of at least 30 degrees at the metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joints [1]. Surgical excision of the diseased tissue has been the gold standard treatment [2]. However, surgery can be costly with potential for wound breakdown, infection, recurrence, and risk for neurovascular injury. Thus, nonsurgical options have been explored that can be implemented in an office-based setting, decrease morbidity, decrease cost and recovery time, but still improve function and quality of life [3]. Collagenase Clostridium histolyticum (CCH) injections have become a popular nonsurgical treatment option that have shown excellent outcomes in properly selected patients [4]. Xiaflex®, a commercial CCH specifically designed for medical purposes, was FDA approved in 2010 and has clear guidelines for appropriate use to optimize benefits and reduce risks.